Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of MP4CO for acute treatment of vaso-occlusive crises in sickle cell disease
2013-001600-11Phase 2Terminated
- Sponsor
- Sangart
- Start
- Jul 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mp4co in sickle cell disease (SCD) and vaso-occlusive crisis (VOC) (2 arms), sponsored by Sangart. Primary endpoint: Time to VOC resolution. Started Jul 2013; status: terminated.
02
Drugs
mp4co
03
Conditions
sickle cell disease (SCD)vaso-occlusive crisis (VOC)
Beyond the preview
Go deeper on 2013-001600-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001600-11.